AR080875A1 - Inhibidores de la actividad de la proteina tirosina quinasa - Google Patents

Inhibidores de la actividad de la proteina tirosina quinasa

Info

Publication number
AR080875A1
AR080875A1 ARP110101195A ARP110101195A AR080875A1 AR 080875 A1 AR080875 A1 AR 080875A1 AR P110101195 A ARP110101195 A AR P110101195A AR P110101195 A ARP110101195 A AR P110101195A AR 080875 A1 AR080875 A1 AR 080875A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocyclyl
group
optionally substituted
cycloalkyl
Prior art date
Application number
ARP110101195A
Other languages
English (en)
Spanish (es)
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of AR080875A1 publication Critical patent/AR080875A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP110101195A 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa AR080875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16

Publications (1)

Publication Number Publication Date
AR080875A1 true AR080875A1 (es) 2012-05-16

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110101195A AR080875A1 (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa
ARP110101191A AR080871A1 (es) 2010-04-16 2011-04-08 Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110101191A AR080871A1 (es) 2010-04-16 2011-04-08 Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa

Country Status (19)

Country Link
US (3) US8455484B2 (https=)
EP (2) EP2563794A4 (https=)
JP (2) JP2013525286A (https=)
KR (2) KR20130058006A (https=)
CN (2) CN103025740B (https=)
AR (2) AR080875A1 (https=)
AU (2) AU2011241422B2 (https=)
CA (2) CA2796054A1 (https=)
CO (2) CO6630193A2 (https=)
EA (2) EA201291052A1 (https=)
MX (2) MX2012012031A (https=)
MY (1) MY157319A (https=)
NZ (2) NZ602948A (https=)
PH (2) PH12012502070A1 (https=)
SG (2) SG184883A1 (https=)
TW (2) TW201204735A (https=)
UA (1) UA108878C2 (https=)
WO (2) WO2011127565A1 (https=)
ZA (2) ZA201207482B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
KR101257343B1 (ko) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Vegf 수용체 및 hgf 수용체 신호전달 억제제
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0908573A2 (pt) * 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
WO2011127567A1 (en) 2011-10-20
AU2011241420B2 (en) 2015-04-16
CO6640224A2 (es) 2013-03-22
SG184882A1 (en) 2012-11-29
AR080871A1 (es) 2012-05-16
CN102947315A (zh) 2013-02-27
WO2011127565A1 (en) 2011-10-20
MX2012012032A (es) 2012-12-17
CN103025740B (zh) 2015-07-01
ZA201207482B (en) 2013-09-25
UA108878C2 (ru) 2015-06-25
EP2563795A1 (en) 2013-03-06
CO6630193A2 (es) 2013-03-01
EA201291052A1 (ru) 2013-04-30
EP2563795A4 (en) 2013-10-23
EP2563794A4 (en) 2013-12-04
CA2796008A1 (en) 2011-10-20
NZ602954A (en) 2014-11-28
PH12012502073A1 (en) 2013-02-11
PH12012502070A1 (en) 2015-05-08
TW201204735A (en) 2012-02-01
US20110257100A1 (en) 2011-10-20
CA2796054A1 (en) 2011-10-20
MY157319A (en) 2016-05-31
CN103025740A (zh) 2013-04-03
AU2011241422A1 (en) 2012-11-01
KR20130100234A (ko) 2013-09-10
EP2563794A1 (en) 2013-03-06
TW201204734A (en) 2012-02-01
SG184883A1 (en) 2012-11-29
US20110257175A1 (en) 2011-10-20
JP2013523846A (ja) 2013-06-17
US8455484B2 (en) 2013-06-04
JP2013525286A (ja) 2013-06-20
NZ602948A (en) 2014-09-26
AU2011241422B2 (en) 2015-05-07
EA201291055A1 (ru) 2013-09-30
MX2012012031A (es) 2012-12-17
KR20130058006A (ko) 2013-06-03
US20140315801A1 (en) 2014-10-23
US8906852B2 (en) 2014-12-09
ZA201207557B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
AR080875A1 (es) Inhibidores de la actividad de la proteina tirosina quinasa
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12018500763A1 (en) New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
AR087913A1 (es) Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c
MX2020007271A (es) Sales y cristales novedosos.
WO2012101065A3 (en) Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors
UY35275A (es) Derivados de aminopirazina
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
EA201992679A1 (ru) N-замещенные индольные производные
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR078951A1 (es) Esferoides de farmacos revestidos y usos de los mismos para la eliminacion o reduccion de afecciones tales como emesis y diarrea
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
EA202190245A1 (ru) Производные спирохромана
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
ZA202106815B (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure